ISSN: 0214-1582
e-ISSN: 1578-1399

See more Open Access Option

Indexed in:

Scopus, ScienceDirect , IBECS

Subscribe:

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

6.6

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.118

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.139

View more metrics

Journal Information

Back to article

Statistics

Follow this link to access the full text of the article

Original Article

Triose phosphate isomerase 1 in serum of women with breast cancer

Triosa fosfato isomerasa 1 sérica en mujeres con cáncer de mama

Obaida Adnan Jwameera,

Corresponding author

obaida.adnan@st.tu.edu.iq

Corresponding author.

, Ekhlas Abdallah Hassanb, Faiz M. Al-Abadya

a Department of Chemistry, College of Science, Tikrit University, Tikrit, Iraq

b Department of Chemistry, College of Science, University of Diyala, Diyala, Iraq

Read

Times
was read the article

Total PDF

Total HTML

Share statistics

Article information

ISSN: 02141582
Original language: English

DOI:10.1016/j.senol.2024.100647

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	3	3	6

Follow this link to access the full text of the article

Publish in

Revista de Senología y Patología Mamaria - Journal of Senology and Breast Disease

Revista de Senología y Patología Mamaria - Journal of Senology and Breast Disease is a member and subscribes the principles of, the Committee on Publication Ethics (COPE)
www.publicationethics.org.

Revista de Senología y Patología Mamaria - Journal of Senology and Breast Disease follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals

Indexed in:

Follow us:

Subscribe:

Statistics

Subscribe to our newsletter